In 6,700 propensity-matched obese patients who underwent atrial fibrillation ablation, GLP-1 receptor agonist users had 18% lower AF recurrence, 27% lower mortality, and 20% fewer heart failure hospitalizations.
27% lower mortalityGLP-1 drug users had significantly reduced all-cause mortality (HR 0.73) after AF ablation, alongside 18% less AF recurrence and 20% fewer heart failure hospitalizations
What the researchers found
Among 6,700 propensity-matched obese patients (matched on 82 variables), GLP-1RA users had significantly lower AF recurrence after ablation: 6.66% vs. 7.72% (HR 0.82, 95% CI 0.76–0.88, p=0.01). All-cause mortality was 27% lower (HR 0.73, 95% CI 0.59–0.91, p=0.01). Heart failure hospitalization was 20% lower (HR 0.80, 95% CI 0.71–0.90, p=0.001). There was no significant difference in need for repeat ablation procedures. These benefits were observed over a median 2-year follow-up (IQR 0.8–3.2 years).
Why it matters
AF recurrence after ablation is a major clinical problem, affecting 20-40% of patients within the first year. Obesity is a key risk factor for recurrence, and no medication has been proven to consistently reduce AF recurrence post-ablation. If GLP-1 drugs can reduce AF recurrence — potentially by addressing the obesity-related atrial substrate changes, inflammation, and autonomic dysfunction that drive the arrhythmia — they could become a standard adjunctive therapy for obese patients undergoing AF ablation.
How the study worked
Retrospective cohort study using the TriNetX research network (>100 million patient records). Included adult obese patients (BMI >30) who underwent AF ablation between January 2015 and January 2025. Cohorts were divided into GLP-1RA users (n=3,350) and non-users (n=3,350), with 1:1 propensity score matching across 82 clinical and demographic variables including age, sex, race, AF subtype, cardiovascular comorbidities, and medications.
What this study cannot tell us
This is a retrospective observational study, so it cannot prove causation. Despite matching on 82 variables, residual confounding is possible — GLP-1RA users may differ from non-users in unmeasured ways. The TriNetX database relies on electronic health records, which may have coding inaccuracies for AF recurrence detection. The study could not determine which specific GLP-1 drugs were used or at what doses. The absolute difference in AF recurrence (6.66% vs. 7.72%) is relatively small, though the mortality and hospitalization reductions are more clinically significant.
How to read the evidence
This is a large, well-matched retrospective observational study from a database of over 100 million patients, with propensity score matching on 82 variables. While it provides strong real-world evidence, it cannot establish causation, and a randomized controlled trial would be needed for definitive proof.
When this study was published
Published in 2026 in Circulation: Arrhythmia and Electrophysiology, this is among the first large studies to examine GLP-1 drugs' effects on AF ablation outcomes in obese patients.
The bigger picture
GLP-1 drugs continue to reveal cardiovascular benefits beyond their metabolic effects. While heart failure reduction and atherosclerotic event prevention are now well-established, the potential anti-arrhythmic effect is a newer finding. AF is the most common cardiac arrhythmia worldwide, and obesity is one of its strongest modifiable risk factors. If GLP-1 drugs can improve AF outcomes by addressing the metabolic and inflammatory substrate of the arrhythmia, this adds a major new indication to their expanding clinical profile.
Questions still open
- Would a randomized trial confirm the anti-arrhythmic effects of GLP-1 drugs in obese patients undergoing AF ablation?
- Is the AF recurrence reduction driven primarily by weight loss, or do GLP-1 drugs have direct anti-arrhythmic effects on atrial tissue?
- Should GLP-1 drugs become standard pre- or post-ablation therapy for obese AF patients?
Common questions
Can GLP-1 drugs help prevent atrial fibrillation from coming back after ablation?
Why might weight loss drugs help with heart rhythm problems?
Read the original research
Impact of GLP-1 Receptor Agonist Therapy on Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients: A Real-World Data Analysis.
Circulation. Arrhythmia and electrophysiology, 19(1), e014101
Citation
Venier, Sandrine; Defaye, Pascal; Lochon, Lisa; Benali, Rémi; Bisson, Arnaud; Carabelli, Adrien; Diouf, Youssou; Jacon, Peggy; Fauchier, Laurent. (2026). Impact of GLP-1 Receptor Agonist Therapy on Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients: A Real-World Data Analysis.. Circulation. Arrhythmia and electrophysiology, 19(1), e014101. https://doi.org/10.1161/CIRCEP.125.014101